INTRODUCTION {#s1}
============

Intracranial germ cell tumors (iGCTs) occur mostly in children and young adults. They account for 3-5% of pediatric CNS tumors with a five- to eightfold higher incidence in East Asia than in Western countries and affect more male than female patients (3:1) \[[@R1]--[@R3]\]. iGCTs are classified into pure germinomas and nongerminomatous germ cell tumors (NGGCT), including teratoma, embryonal carcinoma, yolk sac tumor, choriocarcinoma and malignant mixed iGCTs compound of teratomas and one or more of the other histologies. Pure germinoma is the most common subtype followed by mixed iGCTs. An important prognostic factor is the tumor\'s histology. Pure germinomas are very sensitive to radio- and chemotherapy leading to a 5-year survival rate of more than 90%. In contrast, mixed iGCTs vary in radio- and chemotherapeutic sensitivity; with 5-year survival rates less than 60% \[[@R4]\] for multi-modal therapy. Even though survival rates for germinomas are high long-term outcomes and late effects of radio- and chemotherapy including secondary neoplasms, endocrine deficiencies and strokes, demonstrate that further research with regard to targeted therapy is necessary \[[@R5]\].

The cellular origin of iGCTs is still unclear and controversial. For a long time, a popular hypothesis suggested that all GCTs originate from primordial germ cells (PGCs) migrating in the midline during development. Recent studies argue that iGCTs may develop from neural stem cells \[[@R6]--[@R8]\]. In addition, tumor biology underlying the pathogenesis of these tumors is also largely unknown and therefore a subject of current research. However, mutations and other alterations in the KIT/RAS- and AKT/mTOR pathway, as well as gains of chromosomes 12p or X are common biological/genetic alterations in iGCTs and seem to play a crucial role in the tumorigenic process \[[@R9]--[@R14]\] although their impact on survival is still unclear.

Gain-of-function-mutations of the tyrosine kinase KIT lead to a permanent pathological activation of this transmembrane protein, independent of binding its ligand stem cell factor (SCF) \[[@R15]\]. This results in an increased and steady stimulation of cell proliferation. A similar mechanism is described for *RAS* mutations, in particular *HRAS*, *KRAS* and *NRAS*. These small G-proteins play a central part in diverse signalling pathways and are activated by binding GTP. Point mutations in the active center often lead to an inability to bind GTPase which induces stimulation of cell growth \[[@R16]\].

Due to the fact that iGCTs are more frequent in East Asia than in the West, previous studies included mostly Asian patients. Our study is the first genetic analysis of a larger series of germinomas from Caucasian patients. Moreover, we provide immunohistochemical data on global DNA methylation and examined activation of ERK pathway to elaborate further information on the cell of origin, pathogenetic pathway(s) as well as potential novel therapeutic targets.

RESULTS {#s2}
=======

Clinical features {#s2_1}
-----------------

This study enrolled 55 patients with a median age at diagnosis of 17 years, ranging from 8 to 40 years (Table [1](#T1){ref-type="table"}). There were 47 (85.5%) male and 8 (14.5%) female patients. Tumors included in this cohort predominantly affected the region of the pineal gland (31 of 55 \[56.4%\]) and the suprasellar region (11 of 55 \[20%\]). 6 germinomas (10.9%) revealed bifocal tumor location, 6 (10.9%) were located in other regions of the brain (pons, hypothalamus and lateral ventricle) and for 1 case (1.8%) information about the exact location was not available. For 33 cases survival data was available, revealing that no patient had metastasis, 6 showed subsequent events and 2 patients died. These 33 patients were all of Caucasian ethnicity. In addition, there was no indication of an Asian or Afroamerican ethnic background from the available data of the other cases. 54 tumors were diagnosed as pure germinomas, only 1 case was considered as mixed GCT with large germinoma contents and a teratoma component. All 55 cases showed c-Kit and Oct4 expression, which are recognized diagnostic criteria for germinomas.

###### Clinical data, genetic alteration status and ERK-/ Akt/mTOR activation in 55 germinoma cases

  Case No.   Histology                                       Age   Sex   Location      DNA hypomethylation   stable Genome   MIP amplification   c-Kit mutation   RAS mutation   ERK activation   Akt/mTOR activation   Event   Death
  ---------- ----------------------------------------------- ----- ----- ------------- --------------------- --------------- ------------------- ---------------- -------------- ---------------- --------------------- ------- -------
  1          Germinoma                                       12    m     Suprasellar   yes                   no              no                  no               yes            yes              yes                   no      no
  2          Germinoma                                       11    f     bifocal       yes                   no              no                  yes              no             no               yes                   yes     yes
  3          Germinoma                                       12    m     Pinealis      yes                   no              chr. 12p12          no               no             yes              yes                   yes     yes
  4          Germinoma                                       19    m     Pinealis      yes                   no              no                  no               no             yes              yes                   yes     no
  5          Germinoma                                       15    m     Pinealis      yes                   no              no                  no               yes            yes              yes                   no      no
  6          Germinoma                                       10    m     other         yes                   no              no                  no               no             yes              yes                   no      no
  7          Germinoma                                       15    f     Suprasellar   yes                   no              chr. 12p12          no               no             yes              yes                   no      no
  8          Germinoma                                       13    f     Suprasellar   yes                   no              no                  no               no             no               yes                   no      no
  9          Germinoma                                       21    m     other         yes                   no              no                  no               no             yes              yes                   n.a.    n.a.
  10         Germinoma                                       14    m     Pinealis      yes                   no              no                  no               no             n.a.             yes                   yes     no
  11         Germinoma                                       31    m     other         yes                   no              no                  no               yes            yes              yes                   no      no
  12         Germinoma                                       17    m     bifocal       yes                   no              chr. 11p15.2        no               no             yes              yes                   no      no
  13         Germinoma                                       11    m     Pinealis      yes                   no              no                  no               no             no               yes                   no      no
  14         Germinoma                                       13    f     Suprasellar   yes                   no              chr. 12p12          no               no             yes              yes                   n.a.    n.a.
  15         Germinoma                                       17    m     bifocal       yes                   no              chr. 12p12          no               no             yes              no                    no      no
  16         Germinoma                                       18    m     Pinealis      n.a.                  no              no                  no               yes            n.a.             n.a.                  n.a.    n.a.
  18         Germinoma                                       13    m     Suprasellar   yes                   no              no                  no               yes            yes              yes                   no      no
  19         Germinoma                                       13    m     Pinealis      yes                   no              no                  no               yes            yes              yes                   no      no
  20         Germinoma                                       15    f     Suprasellar   yes                   no              no                  yes              no             yes              yes                   no      no
  21         Germinoma                                       11    m     Pinealis      yes                   no              no                  no               yes            yes              yes                   no      no
  22         Germinoma                                       21    m     Pinealis      yes                   no              no                  no               no             yes              yes                   n.a.    n.a.
  23         Germinoma                                       24    m     Pinealis      yes                   no              no                  yes              no             yes              yes                   n.a.    n.a.
  24         Germinoma                                       18    m     Pinealis      yes                   no              chr. 4q12           no               no             yes              yes                   no      no
  25         Germinoma                                       15    m     Pinealis      yes                   no              no                  no               yes            yes              yes                   no      no
  27         Germinoma                                       17    m     Pinealis      yes                   no              no                  no               no             yes              yes                   no      no
  28         Germinoma                                       11    m     Pinealis      yes                   no              no                  no               yes            yes              yes                   no      no
  29         Germinoma                                       14    m     bifocal       yes                   no              chr. 12p12          no               no             yes              yes                   no      no
  30         Germinoma                                       17    m     Pinealis      yes                   no              no                  no               no             yes              yes                   n.a.    n.a.
  31         Germinoma                                       16    m     Pinealis      yes                   no              no                  no               no             yes              yes                   no      no
  33         Germinoma                                       16    m     Pinealis      yes                   no              no                  yes              no             yes              yes                   no      no
  34         Germinoma                                       24    m     Pinealis      yes                   no              no                  no               no             yes              yes                   n.a.    n.a.
  36         Germinoma                                       22    m     Pinealis      yes                   no              no                  no               no             yes              yes                   n.a.    n.a.
  37         Germinoma                                       40    m     Suprasellar   yes                   no              no                  no               no             yes              yes                   n.a.    n.a.
  38         Germinoma                                       18    m     other         yes                   no              no                  no               yes            yes              yes                   n.a.    n.a.
  39         Germinoma                                       20    m     Suprasellar   yes                   no              no                  yes              no             yes              yes                   n.a.    n.a.
  40         Germinoma                                       11    m     Suprasellar   yes                   no              no                  no               no             yes              yes                   n.a.    n.a.
  41         Germinoma                                       19    m     Pinealis      yes                   no              no                  no               no             yes              yes                   no      no
  42         mixed GCT (Germinoma with teratoma component)   11    m     other         yes                   no              no                  no               yes            yes              yes                   no      no
  43         Germinoma                                       10    m     bifocal       yes                   no              no                  yes              no             no               yes                   no      no
  44         Germinoma                                       17    m     Pinealis      yes                   no              no                  no               yes            yes              yes                   n.a.    n.a.
  45         Germinoma                                       19    f     bifocal       yes                   no              no                  no               no             yes              yes                   no      no
  46         Germinoma                                       8     f     Suprasellar   yes                   no              no                  no               no             yes              yes                   no      no
  47         Germinoma                                       8     m     Pinealis      yes                   no              no                  no               no             yes              yes                   no      no
  48         Germinoma                                       13    m     n.a.          yes                   no              no                  no               no             yes              yes                   n.a.    n.a.
  49         Germinoma                                       28    m     Pinealis      yes                   no              no                  no               no             no               no                    n.a.    n.a.
  50         Germinoma                                       29    m     Pinealis      yes                   no              no                  yes              no             yes              yes                   n.a.    n.a.
  51         Germinoma                                       27    m     Pinealis      yes                   no              no                  no               no             yes              yes                   n.a.    n.a.
  52         Germinoma                                       25    m     Pinealis      yes                   no              no                  yes              no             yes              yes                   n.a.    n.a.
  53         Germinoma                                       24    m     Pinealis      yes                   n.a.            n.a.                n.a.             n.a.           yes              yes                   n.a.    n.a.
  54         Germinoma                                       20    m     Pinealis      yes                   no              no                  n.a.             n.a.           yes              yes                   n.a.    n.a.
  55         Germinoma                                       21    f     other         yes                   n.a.            n.a.                n.a.             n.a.           yes              yes                   no      no
  17         Germinoma                                       34    m     Pinealis      yes                   yes             no                  no               no             no               no                    n.a.    n.a.
  26         Germinoma                                       19    m     Pinealis      yes                   yes             no                  no               no             yes              yes                   n.a.    n.a.
  32         Germinoma                                       12    m     Pinealis      yes                   yes             no                  no               no             yes              yes                   no      no
  35         Germinoma                                       13    m     Suprasellar   yes                   yes             no                  no               no             n.a.             yes                   no      no

Germinoma 17, 26, 32 and 35 are listed at the end and marked grey, because they are excluded from MIP and mutation analysis due to their minimal content of tumor cells. Bifocal location stands for tumor occurrence in both pineal gland and suprasellar region.

Most interestingly we discovered an association between female gender and age ≤ 15 years (p=0.004) as well as suprasellar tumor location (p=0.016). Conversely, male gender was associated with age \>15 years (p=0.004) and pineal tumor location (p=0.023) (Figure [1](#F1){ref-type="fig"}). Survival data of 33 patients treated according the SIOP/HIT germ cell tumor protocols were available. Progression-free survival or overall survival did not correlate to the genetical or biological alterations evaluated in this study.

![Correlation with clinico-pathological data\
All p-values refer to the Fisher\'s exact test. p-values \< 0.05 were considered as statistically significant.](oncotarget-07-55026-g001){#F1}

Global hypomethylation of germinomas {#s2_2}
------------------------------------

Immunohistochemical staining against the 5-Methylcytosine (5mC) epitope of DNA was performed on 54 tumor specimens. All examined samples showed no immunoreactivity for 5mC in tumor cell nuclei, indicating that global DNA hypomethylation is the rule in germinomas (Figure [2](#F2){ref-type="fig"}). In contrast, peritumoral and tumor-infiltrating lymphocytes, which are characteristic of germinomas, showed strong nuclear staining for this epigenetic hallmark.

![Representative staining results of pERK, pAkt, pmTOR, pS6 and 5mC\
All four cases revealed ERK and Akt/mTOR pathway activation and global demethylation.](oncotarget-07-55026-g002){#F2}

MIP analysis {#s2_3}
------------

Molecular inversion probe analysis was performed for 53 germinomas for which DNA was available. 4 cases (7.5%) showed a stable genome but histologically, they consisted mostly of lymphocytes with only a minimal amount of germinoma cells. For this reason we excluded them from data analysis. We detected extensive genetic alterations and chromosomal instability in all remaining 49 cases (92.5%) (Figure [3](#F3){ref-type="fig"}). Most frequently, germinomas showed gains on chromosomes 12p (82%), 21q (76%), 8 (67%), 1q (65%) and 7 (59%). Chromosomal losses were less frequent than gains and were most commonly related to chromosomes 13q (45%), 11q (41%), 5q, 9q (both 39%), and 16p (37%).

![Virtual karyogram of 49 germinomas included in this study\
Chromosomal instability was detected by molecular inversion probe (MIP) arrays. Gains are indicated in blue and losses in red. Frequent gains of chromosomes 1q, 7, 8, 12p and 21q as well as losses of 5q, 9q, 11q, 13q, and 16p become obvious.](oncotarget-07-55026-g003){#F3}

Of note, amplification at 12p12, involving *KRAS*, was detected in 5 cases (10.2%) representing the most frequent amplification. In addition, amplification at 4q12 and 11p15.2, affecting *KIT* and *RRAS-2*, were identified in one case (2%) each (Figure [4](#F4){ref-type="fig"}). Loss of *CBL* at chromosome 11q23.3 was found in 8 cases (16.3%).

![Summary of the somatic events\
Each mutation or alteration found in *KIT*, *KRAS*, *NRAS* and *RRAS-2* is a mutually exclusive event in the affected germinoma.](oncotarget-07-55026-g004){#F4}

GISTIC analysis was used to distinguish significant chromosomal aberrations from random background and revealed a substantial number of copy number (CN) alterations in germinomas. 33 CN gains and 14 CN losses were detected within the germinoma genome by setting the significance cut-off to p≤0.001 (Figure [5](#F5){ref-type="fig"}). 94% of gains and 79% of losses included protein-coding regions. Remarkably, CN gains affected the *IL10* (Interleukin-10) gene and genes encoding its receptors *IL10RA, IL10RB* and *IL10RB-AS1* at chromosomes 1q32.1, 11q23.3 and 21q22.11. Moreover, chromosome 4q12, including *KIT*, showed also significant CN gains (Table [2](#T2){ref-type="table"}).

![Statistically significant frequent copy number variations in germinomas analyzed by GISTIC\
Germinomas reveal a high level of genomic instability. P-values ≤ 0.001 were defined as statistically significant. Protein-coding genes in the affected regions are listed.](oncotarget-07-55026-g005){#F5}

###### Protein-coding genes affected by significant CN gains and losses

               Region            Gene         Name
  ------------ ----------------- ------------ ------------------------------------------------------------------------------------------------
  **Gains**                                   
               *Chr. 1p36.22*    PIK3CD-AS1   PIK3CD antisense RNA 1
                                 PIK3CD-AS2   PIK3CD antisense RNA 2
                                 PIK3CD       Phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta
               *Chr. 1p13.3*     CD53         CD53 molecule
               *Chr. 1q21.3*     RPRD2        Regulation of nuclear pre-mRNA domain containing 2
                                 TARS2        Threonyl-tRNA synthetase 2, mitochondrial (putative)
                                 ECM1         Extracellular matrix protein 1
               *Chr. 1q32.1*     IL10         Interleukin 10
               *Chr. 2p22.1*     HNRNPLL      Heterogeneous nuclear ribonucleoprotein L-like
                                 GALM         Galactose mutarotase (aldose 1-epimerase)
                                 SRSF7        Serine/arginine-rich splicing factor 7
               *Chr. 2q32.3*     STK17B       Serine/threonine kinase 17b
                                 HECW2        HECT, C2 and WW domain containing E3 ubiquitin protein ligase 2
               *Chr. 2q37.1*     INPP5D       Inositol polyphosphate-5-phosphatase D
               *Chr. 3p24.1*     TGFBR2       Transforming growth factor, beta receptor II (70/80kDa)
               *Chr. 3q26.31*    TNFSF10      Tumor necrosis factor (ligand) superfamily, member 10
               *Chr. 4p14*       RHOH         Ras homolog family member H
               *Chr. 4q12*       KIT          v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog
               *Chr. 6p22.2*     HIST1        Histone cluster 1
               *Chr. 7p15.2*     NFE2L3       Nuclear factor, erythroid 2-like 3
                                 HNRNPA2B1    Heterogeneous nuclear ribonucleoprotein A2/B1
               *Chr. 7q36.1*     GIMAP4       GTPase, IMAP family member 4
                                 GIMAP6       GTPase, IMAP family member 6
               *Chr. 8p21.2*     PTK2B        Protein tyrosine kinase 2 beta
               *Chr. 8q24.22*    ST3GAL1      ST3 beta-galactoside alpha-2,3-sialyltransferase 1
               *Chr. 10p12.2*    PIP4K2A      Phosphatidylinositol-5-phosphate 4-kinase, type II, alpha
               *Chr. 11q23.3*    IL10RA       Interleukin 10 receptor, alpha
               *Chr. 12p11.21*   AMN1         Antagonist of mitotic exit network 1 homolog
                                 H3F3C        H3 histone, family 3C
               *Chr. 12q13*      METTL21B     Methyltransferase like 21B
               *Chr. 13q14.13*   LCP1         Lymphocyte cytosolic protein 1 (L-plastin)
               *Chr. 15q26.1*    AEN          Apoptosis enhancing nuclease
               *Chr. 16p13.11*   ABCC1        ATP-binding cassette, sub-family C (CFTR/MRP), member 1
               *Chr. 16q13*      SLC12AB      Solute carrier family 12 (sodium/chloride transporter), member 3
                                 HERPUD1      Homocysteine-inducible, endoplasmic reticulum stress-inducible, ubiquitin-like domain member 1
                                 CETP         Cholesteryl ester transfer protein, plasma
               *Chr. 17q11*      NF1          Neurofibromin 1
                                 EVI2A        Exotropic viral integration site 2A
                                 EVI2B        Exotropic viral integration site 2B
               *Chr. 19p13*      INSR         Insulin receptor
               *Chr. 19q13*      ZNF428       Zinc finger protein 428
               *Chr. 20p12.3*    GPCPD1       Glycerophosphocholine phosphodiesterase 1
               *Chr. 20q13.2*    NFATC        Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2
               *Chr. 21q22.11*   IFNAR2       Interferon (alpha, beta and omega) receptor 2
                                 IL10RB       Interleukin 10 receptor, beta
                                 IL10RB-AS1   IL10RB antisense RNA 1 (head to head)
               *Chr. 22q12.3*    MYH9         Myosin, heavy chain 9, non-muscle
  **Losses**                                  
               *Chr. 1p36.32*    ACTRT2       Actin-related protein T2
                                 PRDM16       PR domain containing 16
               *Chr. 4p16.1*     SORCS2       Sortilin-related VPS10 domain containing receptor 2
               *Chr. 5p15.33*    SDHA         Succinate dehydrogenase complex, subunit A, flavorprotein (Fp)
                                 PDCD6        Programmed cell death 6
                                 AHRR         Aryl-hydrocarbon receptor repressor
                                 EXOC3        Exocyst complex component 3
                                 CEP72        Centrosomal protein 72kDa
                                 SLC9A3       Solute carrier family 9, subfamily A (NHE3, cation proton antiporter 3), member 3
                                 TPPP         Tubulin polymerization promotin protein
                                 ZDHHC11      Zinc finger, DHHC-type containing 11
                                 TRIP13       Thyroid hormone receptor interactor 13
                                 BRD9         Bromodomain containing 9
                                 NKD2         Naked cuticle homolog 2 (Drosophila)
                                 SLC6A18      Solute carrier family 6 (neutral amino acid transporter), member 18
                                 SLC6A19      Solute carrier family 6 (neutral amino acid transporter), member 19
                                 SLC1247      Solute carrier family 12 (potassium/chloride trasporter), member 7
                                 TERT         Telomerase reverse transcriptase
                                 PLEKHG4B     Pleckstrin homology domain containing, family G (with RhoGef domain) member 4B
               *Chr. 8p11.22*    ADAM3A       ADAM metallopeptidase domain 3A (pseudogene)
                                 ADAM5        ADAM metallopeptidase domain 5 (pseudogene)
               *Chr. 9q34*       COL5A1       Collagen, type V, alpha 1
                                 WDR5         WD repeat domain 5
                                 RXRA         Retinoid X receptor, alpha
                                 FCN1         Ficolin (collagen/fibrinogen domain containing) 1
                                 FCN2         Ficolin (collagen/fibrinogen domain containing lectin) 2
                                 OLFM1        Olfactomedin 1
                                 PAEP         Progestogen-associated endometrial protein
                                 OBP2A        Odorant binding protein 2A
                                 PPP1R26      Protein phosphatase 1, regulatory subunit 26
                                 LCN1         Lipocalin 1
               *Chr. 10q26.3*    CFAP46       Cilia and flagella associated protein 46
               *Chr. 11p15.3*    GALNT18      Polypeptide N-acetylgalactosaminyltransferase 18
               *Chr. 11q23.3*    DSCAML1      Down syndrome cell adhesion molecule like 1
               *Chr. 13q34*      ATP11A       ATPase, class VI, type 11A
                                 MCF2L-AS1    MCF2L antisense RNA 1
                                 MCF2L        MCF.2 cell line derived transforming sequence-like
               *Chr. 16p13.2*    GRIN2A       Glutamate receptor, ionotropic, N-methyl D-aspartate 2A
               *Chr. 16q24*      CA5A         Carbonic anhydrase VA, mitochondrial
                                 SLC7A5       Solute carrier family 7 (amino acid transporter light chain, L system), member 5
                                 BANP         BTG3 associated nuclear protein
                                 JPH3         Junctophilin 3
                                 MAP1LC3B     Microtubule-associated protein 1 light chain 3 beta
                                 FENDRR       FOXF1 adjacent non-coding developmental regulatory RNA
                                 FOXF1        Forkhead box F1
                                 FOXC2-AS1    FOXC2 antisense RNA 1

Molecular analysis of *c-Kit* and *RAS* mutations in germinomas {#s2_4}
---------------------------------------------------------------

We examined a total of 51 germinomas and 1 mixed GCT (germinoma and teratoma component) for mutations in *KIT* exons 11, 13, 17 and 18 as well as mutation hotspots in *HRAS*, *KRAS*, *NRAS* and *RRAS-2*. For the 4 cases (7.7%) showing a stable genome in MIP analysis, no mutations could be detected in *KIT* or *RAS*. Due to their minute amount of tumor cells they were excluded from the sequence data analysis.

Sanger sequencing exposed non-silent *KIT* mutations in 8 cases (16.7%) (Figure [6](#F6){ref-type="fig"}). Most mutations affected tyrosine kinase II region (TK2) encoded by exon 17 in terms of point mutations in codons 816 (3/52) and 820 (2/52). In addition, one deletion of codon 560 in exon 11 and 2 point mutations in codon 634 of exon 13 were detected (representative sequencing results of *KIT* mutations are given in Figure [7a](#F7){ref-type="fig"}). No mutation in exon 18 of the *KIT* was observed.

![Somatic *KIT* mutations found in this germinoma cohort in comparison to reported *KIT* mutations in gastrointestinal stromal tumors (GISTs) and seminomas\
Black circles represent the number of cases harboring a given mutation. The functional domains concerned by mutations are juxtamembrane domain (JM) and tyrosine kinase II (TK2). Previously described tyrosine-kinase inhibitors (TKIs) \[imatinib (IM), sunitinib (SU), sorafenib (SO), nilotinib (NI), midostaurin (MI) and dasatanib (DA)\] and there activity against each mutation are shown on the right.](oncotarget-07-55026-g006){#F6}

![**a.** Representative *KIT* mutations detected by Sanger sequencing. **b.** Representative cases of *RAS* mutations detected by pyrosequencing analysis. Pyrograms are compared to wild type and/or positive control data. Significant peak increases and concomitant reductions in germinoma 42 \[*NRAS* Q61R (CAA → CGA)\], 19 \[*RRAS-2* G23S (GGC → AGC)\], 44 \[*RRAS-2* G23A (GGC → GCC)\], 28 \[*RRAS-2* G24C (GGC → TGC)\] and 38 \[*RRAS-2* G24D (GGC → GAC)\] expose mutations in these cases.](oncotarget-07-55026-g007){#F7}

Pyrosequencing analysis of the *RAS* mutation hotspots codon G12, G13 and Q61 in *HRAS*, *KRAS* and *NRAS* as well as their homologous parts codon G23, G24 and Q72 in *RRAS-2*, revealed 12 (25%) non-silent point mutations. Mainly, these point mutations affected the GTP binding domain (Figure [8](#F8){ref-type="fig"}).

![Schematic representation of mutations in *KRAS*, *NRAS* and *RRAS-2*, illustrating involvement of functional gene domains\
Black circles indicate the number of mutations identified.](oncotarget-07-55026-g008){#F8}

Only one point mutation was seen in *KRAS* affecting codon G12. *NRAS* G12 and Q61 were each mutated in 2 tumors and *NRAS* G13 in 1. Most remarkably, no specimen revealed mutations in *HRAS*, but 6 (12.5%) germinomas showed point mutations in the RAS homolog *RRAS-2* of which 4 involved codon G23 and 2 involved codon G24 (representative sequencing results of *RAS* mutations are given in Figure [7b](#F7){ref-type="fig"}).

Altogether, genetic alterations were observed in 27 cases (56.3%) in *KIT* or *RAS* genes which were mutually exclusive (Figure [4](#F4){ref-type="fig"}). Comparison of *KIT*/*RAS* mutation status in germinomas and patient\'s age, sex and tumor location revealed no significant correlations (Figure [1](#F1){ref-type="fig"}).

Immunohistochemical analysis of ERK- and Akt/mTOR-pathway {#s2_5}
---------------------------------------------------------

Immunohistochemical staining against pAkt, pmTOR, pS6 and pERK was performed on 54 GCTs including 53 pure germinomas and 1 mixed GCT (germinoma and teratoma component). Nuclear and cytoplasm staining of these proteins was considered positive.

pERK expression was observed in 46 (88.5%) tumors. Expression scores ranged from 0 to 300 (median, 102). 10 (19.2%) tumor samples showed strong staining for pERK. 24 (46.2%) tumor specimen revealed moderate staining whereas in 12 (23%) cases weak staining was found. No immunoreactivity for pERK was detected in 6 cases (11.5%).

45 (84.9%) tumor specimens showed expression of pAKT. Expression scores ranged from 0 to 300 (median, 101). Strong staining for pAkt was observed in 7 cases (13.2%). We detected moderate staining in 30 (56.6%) and weak staining in 8 (15.1%) samples. Negative staining was seen in 8 (15.1%) tumors.

pmTOR expression was detected in 45 (90%) tumor specimens. Expression scores ranged from 0 to 270 (median, 87). 3 (6%) cases were considered as strongly positive. 40 (80%) samples were rated moderate whereas 2 (4%) tumors disclosed weak staining. 5 (10%) germinomas revealed no immunoreactivity for the used pmTOR antibody.

In contrast to the other stainings, staining for pS6 was generally negative \[31 tumors (57.4%)\]. Only 23 (42.6%) samples revealed immunoreactivity for pS6. Expression scores ranged from 0 to 200 (median, 33). Strong staining was seen in only one (1.9%) case. 14 (25.9%) tumors showed moderate and 8 (14.8%) exhibited weak staining (Figure [9](#F9){ref-type="fig"}).

![Protein expression of pERK, pAkt, pmTOR and pS6 in 54 germinomas\
Graphic presentation of distribution of negative, weak, moderate and strong staining against pERK, pAkt, pmTOR and pS6. pERK, pAkt and pmTOR were frequently expressed whereas pS6 showed more negative results.](oncotarget-07-55026-g009){#F9}

In seven cases, immunostaining could not be assessed because the samples contained only scant tumor cells in the presence of many lymphocytes (1 case for pAkt, 2 cases for pERK and 4 cases for pmTOR).

In summary, 88.5% of germinomas revealed an upregulation of the ERK pathway. Activation of AKT/mTOR pathway was seen in 94.4% of germinomas (illustration of IHC scores in Figure [10](#F10){ref-type="fig"}). Most remarkably, activation of both pathways was detected in 83.3% (representative staining results of cases with activations in both signal pathways are given in Figure [2](#F2){ref-type="fig"}).

![Semiquantitive analysis of pERK, pAkt, pmTOR and pS6 expression by IHC in 54 germinomas\
Staining was scored by multiplying intensity by percentage of stained cells. The result was a score between 0 and 300.](oncotarget-07-55026-g010){#F10}

DISCUSSION {#s3}
==========

Our knowledge about the cellular origin of iGCTs is based on a limited number of studies. Analysis on mouse embryos showed that PGCs physiologically migrate in midline body structures during development, finally residing in the genital ridges \[[@R17]\]. Germ cells that remain in other areas usually die through reduction of stem cell factor signaling which leads to apoptosis of these PGCs \[[@R18]\]. In addition, Hoei-Hansen et al. \[[@R6]\] showed expression of genes associated with embryonic stem cell pluripotency like *PLAP*, *HCG*, *OCT-3/4*, *KIT, AP-2y* and *NANOG* in iGCTs. One hypothesis on the cellular origin of iGCTs is that they are derived from mismigrated PGCs. Alternatively, Tan and Scotting \[[@R7]\] suggested that transformation of endogenous neural stem cells by demethylation of the *OCT-4* promotor results in an upregulation of this gene which might trigger the formation of GCTs. Moreover, they assume that gene-specific methylation and additional genetic events, like *KIT* mutations in germinomas, might play a role in specification of these tumors. However, this hypothesis raises the question on the triggering mechanism involved in the demethylation of neural stem cells. In addition, this model does not explain why expression of c-Kit is not restricted to pure germinomas but also found as component in mixed GCTs \[[@R9]\].

Considering human germ cell development, global hypomethylation is an epigenetic hallmark in primordial germ cells (PGCs) accompanied by high c-Kit expression \[[@R19], [@R20]\]. We examined a large cohort of germinomas and showed that 100% of these revealed global hypomethylation and *c-Kit* expression in immunohistochemical staining, independently of *c-Kit* mutational status. In contrast to germinomas, studies revealed global methylation for yolk sac tumors \[[@R21]\] and non-seminomas \[[@R22]\], indicating a fundamental difference with germinomas in terms of lineage differentiation or cell of origin. Other brain tumor entities including different glioma entities, medulloblastomas and rhabdoid tumors of the CNS have been extensively characterised in the last years by genome-wide methylation profiling and did not show a similar demethylation phenotype \[[@R23]--[@R25]\]. Comparing the *KIT* mutational frequencies of exons 11, 13, 17 and 18 encoding different functional domains between germinomas, seminomas and gastrointestinal germ cell tumors (GISTs) showed strong similarities between seminomas and germinomas but a different distribution for GISTs \[[@R26], [@R27]\]. These results reinforce the genetic similitudes for seminomas and germinomas. Broader information on methylation status and *c-Kit* expression in larger collectives of NGGCTs could further help understanding differences of the pathogenesis in subtypes of iGCTs. Global DNA demethylation demonstrated by immunohistochemistry for 5mC may be a useful tool for the differential diagnosis of iGCTs. In addition, differences in therapeutic response between pure germinomas and NGGCTs could also be related to the tumors\' methylation status.

In our study we showed that global hypomethylation of tumor DNA strikingly coincides with chromosomal instability in germinomas. Previously, Fukushima et al. \[[@R9]\] reported frequent gains of chromosomes 21q (66.7%), 1q (56.7%) and X (53.5%) and loss of chromosome 13q (53.3%) in a larger cohort of germinomas. These findings were confirmed by Wang et al. \[[@R14]\], describing chromosomes X (72.7%) and 21q (63.6%) as frequently amplified and 11q (45.5%), 13q and 17p (both 36.4%) frequently deleted in germinomas. Our findings reinforce these discoveries, showing frequent gains on chromosomes 12p (82%), 21q (76%), 8 (67%), 1q (65%) and 7 (59%) and losses on chromosomes 13q (45%), 11q (41%), 5q, 9q (both 39%), and 16p (37%) in pure germinomas. Of note, chromosome 12p is frequently affected by chromosomal gains in our study. In addition, amplification of 12p12, involving the *KRAS* gene, was detected in 10% of cases. This leads us to assume that amplification of 12p seems to play an important role in germinomas. In the last years, several reports already highlighted the importance of chromosome 12p in testicular GCTs, especially of amplification at 12p11.2-p12.1 \[[@R28]\] and describing it as a genetic hallmark of germ cell tumors \[[@R29]\]. Our results strongly confirm these findings for germinomas. On the other hand, previous studies reported the frequency of 12p gain in germinomas as only 36.7% \[[@R9]\] and 36.4% \[[@R14]\], which is a smaller percentage than in our cohort. We propose three explanations for this finding. First, we examined a larger number of germinomas than in the previous studies and maybe therefore obtained more representative data. Second, we examined only tumors of Caucasian patients whereas the previous studies mostly investigated Asian patients. Geographical genetic differences might explain the results. Third, Fukushima et al. \[[@R9]\] described 10% of germinomas as chromosomally stable. In our initial screening, we also identified 4 germinomas of 53 (7.5%) which showed a stable genome in MIP analysis. However, these tumors had a minute amount of tumor cells (\< 5%) and mainly consisted of lymphocyte infiltrates contrary to the other samples. For this reason, we suspect that allele frequencies of these tumors are too low to be detected as genetic alterations by MIP analysis. This is also corroborated by the fact that these 4 tumors did not reveal any alterations in the mutation analysis (see below). GISTIC analysis revealed significant CN gains in the *IL10* gene and its receptor genes. Sredni et al. \[[@R30]\] showed that autocrine/paracrine IL10 secretion of stomach adenocarcinoma and glioblastoma multiforme cell lines is essential for tumor cell proliferation and inhibition of IL10 leads to decreased cell proliferation. Future studies might show if germinoma proliferation also depends on IL10.

MIP analysis also detected amplifications at 4q12 and 11p15.2, affecting the *KIT* and *RRAS-2* loci in one case each. As described before, physiological primordial germ cell growth is dependent on *KIT* expression and iGCTs show pathological activation of c-KIT and downstream signaling components. For this reason, we statistically examined the *KIT* and *RAS* family member mutational status in our cohort. We found genetic alterations in 17.3% of germinomas for *KIT* and 34.6% for *RAS* whereas Fukushima et al. \[[@R9]\] detected *c-Kit* mutations in 40% and *RAS* mutations in 20%, Wang et al. \[[@R14]\] 25% for *KIT* and 19% for *RAS* and recently Ichimura et al. \[[@R31]\] found *c-Kit* mutated in 40% and *RAS* mutated in 19% of germinomas. In summary, our overall fraction of alterations in *KIT* and *RAS* is similar to the previous studies. However we found a higher percentage of alterations in *RAS* compared to *KIT*. This difference in the distribution between our cohort and the three collectives above might be due to the ethnicity of the patients leading to geographically different frequencies of genetic alterations in germinomas. Remarkably, all alterations in *KIT* and *RAS* were mutually exclusive genetic events in our cohort. Fukushima et al. \[[@R9]\], Wang et al. \[[@R14]\] and Ichimura et al. \[[@R31]\], who found 97% of germinomas having mutually exclusive mutations in *KIT* or *RAS*, confirmed this finding, which strongly suggests that an alteration in one signal component is sufficient to trigger tumorigenesis. Moreover, in our series we identified *RRAS-2* as a new player in germinoma pathogenesis, which we found alterated in 14.6% of cases.

Furthermore, we discovered activation of the Akt/mTOR pathway by immunohistochemistry in 94.4% and upregulation of ERK pathway in 88.5% of germinomas. Activation of both pathways was detected in 83.3%. Interestingly, pS6 was found to be negative in 57.4% of cases indiacting that this component is not the preferentially phosphorylated target of mTOR in germinomas. Indeed, in other cell types such as cerebellar granule neuron precursors it was shown that mTOR is able to induce eIF4E, which is essential for proliferation, and simultaneously suppresses S6 activity, which is needed for cell cycle exit \[[@R32]\]. Therefore, S6 is not necessary for cell proliferation in cerebellar granule neuron precursors. The main mTOR targets in germinomas and their functional roles have to be identified in future studies.

These findings indicate that activation of Akt/mTOR and ERK pathways are general phenomena in germinomas. Therefore, we suspect that the 43.7% of germinomas with no genetic alterations in our study might have alteration in other components of these pathways besides *KIT* and *RAS*. This is supported by Ichimura et al. \[[@R31]\] who found 7% of germinomas mutated for *MTOR* and further tumors mutated in genes of these two pathways.

Current therapy for intracranial germinomas achieves excellent long term survival, albeit at the cost of some morbidity. Targeted inhibition of the ERK and Akt/mTOR pathways might be an option for patients with recurrent tumors of whose tumors fail to respond to first line therapy. Recently, small molecule inhibitors of Akt were tested at different levels of clinical trials \[[@R33]\]. Phase 1 clinical trials showed positive results for the oral Akt inhibitor afuresertib \[[@R34]\]. In addition, *in vitro* studies with the ERK inhibitor SCH772984 in *RAS* mutant cells exhibited promising results \[[@R35]\]. Ichimura et al. \[[@R31]\] showed that mTor mutant cells which were treated with the mTor inhibitor pp242 showed dose-dependent downregulation of the Akt/mTor pathway. Combining ERK and Akt/mTOR inhibitors might be a therapeutic option for patients with recurrences that could be related to over compensatory hyperactivation of the parallel signal pathway, when only one pathway was inhibited before. However, the dependence of tumor cells on these pathways has to be proven when tumor models become available and further investigations are required to examine targeted therapy options for germinomas.

MATERIALS AND METHODS {#s4}
=====================

Tumor specimen {#s4_1}
--------------

The study includes 54 histologically verified pure germinomas and 1 mixed intracranial germ cell tumor which contained large germinoma parts and some teratoma components. Tumor specimens were retrieved from the archives of the Institute of Neuropathology, University of Bonn Medical Center (Bonn, Germany), of the DGNN German Brain Tumor Reference Center (Bonn, Germany) and the German Paediatric Tumor Registry (Kiel, Germany). All tumors were diagnosed according to the WHO classification of tumors of the central nervous system \[[@R36]\] using histological and immunohistochemical methods.

DNA extraction {#s4_2}
--------------

Hematotoxylin-eosin (H&E) --stained sections of each case were examined carefully before DNA extraction. DNA from 53 formalin-fixed paraffin-embedded (FFPE) tumors was extracted using the QIAamp DNA Mini Tissue Kit (Qiagen GmbH; Düsseldorf, Germany) according to the manufacturer\'s protocol. All tissue samples were used in an anonymous manner, as approved by the ethics committee at the University of Bonn Medical Center (Bonn, Germany).

Molecular inversion profiling {#s4_3}
-----------------------------

To identify copy number gains and losses, we used an MIP array using OncoScan FFPE Express 330K Platform Version 2 (Affymetrix, Santa Clara, CA, USA). The molecular inversion probe assay of 53 germinoma samples was performed as already described \[[@R37]\]. By using Nexus Copy Number 7.0 Discovery Edition software (BioDiscovery, El Segundo, CA, USA) the raw MIP data file was analyzed. To make copy number and loss of heterozygosity calls, BioDiscovery\'s SNP-FASST2-Segmentation algorithm was used. Genomic Identification of Significant Targets in Cancer (GISTIC) analysis was used to distinguish significant chromosomal aberrations from random background \[[@R38]\].

*KIT* mutation analysis {#s4_4}
-----------------------

52 tumors were screened for mutations in *KIT* exons 11, 13, 17 and 18 by direct sequencing. Therefore, polymerase-chain-reaction-products were purified using a PCR purification kit (Qiagen) and sent to a commercial sequencing service (Eurofins MWG Operon, Ebersberg, Germany), where direct sequencing of DNA was performed in duplicate (forward and reverse) using 30 ng of PCR products.

Pyrosequencing analysis for mutation hot spots of *NRAS*, *KRAS*, *HRAS* and *RRAS-2* {#s4_5}
-------------------------------------------------------------------------------------

52 specimens were analyzed for hot spot mutations in the RAS genes *NRAS*, *KRAS*, *HRAS* and *RRAS-2*. PCR amplification primers flank the homologous hotspot regions of these genes. For the pyrosequencing reaction, single-stranded DNA templates were immobilized on streptavidin-coated Sepharose high-performance beads (GE Healthcare, Uppsala, Sweden) using the PSQ Vacuum Prep Tool and Vacuum Prep Worktable (Biotage, Uppsala, Sweden), according to the manufacturer\'s instructions. Then DNA was incubated at 80°C for two minutes and allowed to anneal to 0.4 mmol/L sequencing primer at room temperature. Pyrosequencing was performed using PyroGold Reagents according to the manufacturer\'s protocol. Positive and negative controls were used to compare results. Pyrograms were analyzed by PyroMark Q24 software (Biotage), using the allele quantification (AQ) software to determine the percentage of mutant versus wild type alleles according to percentage relative peak height. A sequential nucleotide dispensation protocol was used, reflecting the expected order of nucleotide incorporation and the potential base change within the first, second or third position of the hot spot codons G12, G13 and Q61 of *HRAS*, *NRAS* and *KRAS*. In the same manner codons G23, G24 and Q72 of *RRAS-2* were examined. Peak heights are proportional to the number of nucleotides that are incorporated with each dispensation.

Immunohistochemistry {#s4_6}
--------------------

Paraffin-embedded tissue samples were divided into serial sections of 4 μm. Positively charged slides were cut, air dried overnight at 37°C, deparaffinized in xylene and rehydrated in a degraded alcohol sequence. Slides were then microwaved in 10 mmol/L citrate buffer (pH 6.0) for antigen retrieval, followed by incubation in 3% hydrogen peroxide for 5 minutes at room temperature to block the activity of endogenous peroxidase and in blocking solution (CSA II Kit; Dako, Glostrup, Denmark). Tumors were incubated overnight with primary antibodies \[pAkt Ser473, 1:200, rabbit monoclonal antibody (736E11, Cell Signaling Technology, Leiden, Netherlands); pERK Thr202/Tyr204, 1:200, rabbit monoclonal antibody (20G11, Cell Signaling Technology); pS6 Ser235/236, 1:200, rabbit monoclonal antibody (91B2, Cell Signaling Technology); pmTOR Ser2448, 1:50, rabbit monoclonal antibody (49F9, Cell Signaling Technology); 5-Methylcytosine, 1:8000, mouse monoclonal antibody (BI-MECY, IgG1, Eurogentec, Seraing, Belgium)\]. Sections were washed in Tris-buffered saline with Tween 20. Visualization of bound antibodies was achieved by the CSA system embodies technology (CSA II, Biotin-Free catalyzed Amplification System; Dako). Slides were counterstained with hematoxylin and dehydrated in a graded alcohol sequence and mounted in Richard-Allan Scientific Cytoseal XYL (Thermo Scientific, Waltham, MA).

Two authors blinded for clinical and genomic data evaluated the percentage of stained cells and scored the samples for staining intensity (0 = negative, 1 = weak intensity, 2 = moderate intensity, 3 = strong intensity). The results were used to calculate a score between 0 and 300 by multiplying the percentage of stained cells by intensity, and tumor samples were classified into negative staining (score 0-9), weak staining (score 10-49), moderate staining (score 50-199) and strong staining (score 200-300).

Statistical analysis {#s4_7}
--------------------

Significantly overrepresented factor values in a particular factor group were identified using the one-tailed Fisher\'s Exact test at a p-value of 0.05. The log-rank test statistic \[[@R39]\] was used to identify regions yielding a high degree of survival prediction. p-values were calculated based on a Chi-Squared test and p-value ≤ 0.05 were considered significant. To compare survival times, Kaplan-Meier curves were generated. The p-values were computed using the log-rank test \[[@R39]\].
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